Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Ofer Margalit^*, William S. Harmsen, Einat Shacham-Shmueli, Molly M. Voss, Ben Boursi, Anna D. Wagner, Romain Cohen, Curtis L. Olswold, Leonard B. Saltz, Daniel A. Goldstein, Herbert Hurwitz, Niall C. Tebbutt, Fairooz F. Kabbinavar, Richard A. Adams, Benoist Chibaudel, Axel Grothey, Takayuki Yoshino, John Zalcberg, Aimery de Gramont, Qian ShiHeinz Josef Lenz

^*Corresponding author for this work

Oncology
Epidemiology & Preventive Medicine

Sheba Medical Center at Tel Hashomer
Mayo Clinic Rochester, MN
Mayo Clinic Scottsdale, AZ
University of Lausanne
Sorbonne Université
Memorial Sloan-Kettering Cancer Center
Rabin Medical Center Israel
Duke University
University of Melbourne
Austin Health
University of California at Los Angeles
Velindre University NHS Trust
Franco-British Institute
West Cancer Center
National Cancer Center Japan
Monash University
University of Southern California

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Sort by
Weight
Alphabetically

Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Fingerprint

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Neuroscience